Biogen (BIIB) AI Stock Analysis

Biogen

(BMV:BIIB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Growth Portfolio MomentumRapid growth in the newer portfolio is reducing reliance on Biogen’s legacy MS franchise and broadening its revenue base. The portfolio’s increasing contribution supports a more durable return to growth, provided adoption remains strong across its neurological and specialty products.

Negative Factors

Profitability CompressionThe sharp decline in operating and net margins weakens earnings durability even though revenue is growing modestly. Lower profitability reduces the cash available per dollar of sales and can constrain investment capacity if higher launch and development spending persists.

Biogen (BIIB) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 37.49B
Dividend Yield: ―
Average Volume (3M): 27
Price to Earnings (P/E): 107.5
Beta (1Y): -0.03
Revenue Growth: -8.51%
EPS Growth: -80.83%
Country: Mexico
Employees: 7,500
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Biogen Business Overview & Revenue Model

Company Description

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addre...

Biogen Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 16, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. Biogen reported double-digit revenue growth, accelerating growth-portfolio performance, rapid Appellis synergy capture, strong adoption of key products, record early-stage pipeline productivity, solid free cash flow, debt repayment, and higher 2026 EPS guidance. The main challenges were VUMERITY's formulary-driven decline, acquisition-related charges and higher operating expenses, expected Q4 inventory and revenue normalization, SYFOVRE discontinuation levels, and uncertainty around upcoming clinical readouts.

Positive Updates

Total Revenue Growth

Third-quarter total revenue was $2.8 billion, up 11% year over year, marking an acceleration in the top-line growth trajectory and benefiting from the Appellis acquisition.

Negative Updates

VUMERITY Revenue Decline

VUMERITY revenue was $192 million, down 11% year over year and 2% quarter over quarter. Revenue was affected by tighter Part D formulary management, and management expects this dynamic to continue affecting Part D drugs this year.

Company Guidance

Biogen expects to return to top line growth in 2026; full year 2026 non-GAAP diluted EPS guidance is between $12.20 and $13.00, with approximately $50 million of acquired IPR&D in the fourth quarter. Q4 global SPINRAZA revenue is expected to be up approximately a mid single digit percentage versus the fourth quarter of 25, Q4 VUMERITY revenue is expected to be roughly flat sequentially or up approximately a mid single digit percentage versus the fourth quarter of 25, and Q4 SYFOVRE revenue is expected to be up approximately a mid single digit percentage versus the $155 million reported by Appellis in the fourth quarter of 25; SKYCLARYS inventory of approximately $12 million and SYFOVRE inventory of approximately $11 million are expected to be drawn down in Q4. The Appellis transaction is expected to be less dilutive in 2026 and accretive to non GAAP diluted EPS in 2027, generating at least $250 million of run rate synergies by the end of 2027, while Biogen expects to repay the remaining $1.4 billion of term loans by the end of 27; at least 50% of covered lives are expected to have coverage for LEQEMBI iClick in both the initiation and maintenance administrations starting in 2027.

Biogen Risk Analysis

Biogen disclosed 30 risk factors in its most recent earnings report. Biogen reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Biogen Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:BIIB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LLY	81Outperform	$1.33T	45.89	83.65%	0.47%	45.51%	50.48%
ABBV	72Outperform	$521.11B	83.08	-223.75%	2.35%	10.68%	―
NVS	72Outperform	$297.25B	31.19	24.24%	2.95%	1.64%	-28.72%
SNY	71Outperform	$107.18B	24.39	5.52%	5.46%	23.68%	-30.90%
JNJ	70Outperform	$657.68B	41.42	19.55%	1.93%	7.81%	-35.95%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:BIIB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:BIIB	Biogen Inc.	4689.60	1899.60	68.09%
LLY	Eli Lilly And Company	1417.54	526.63	59.11%
JNJ	Johnson & Johnson	273.20	91.04	49.98%
NVS	Novartis AG	160.79	39.31	32.36%
SNY	Sanofi SA	44.34	-3.79	-7.87%
ABBV	Abbvie	294.89	89.09	43.29%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Biogen AI Stock Analysis